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Abstract
Background: Human Immunodeficiency Virus (HIV) and Schistosomiasis co-infection is common among residents at
the shores of Lake Victoria in Kenya. About 36% of this population initiating antiretroviral therapy (ART) experience
Immune Reconstitution Inflammatory Syndrome (IRIS) that complicates recovery. Several IL-23R alleles have been
associated with susceptibility to both autoimmune and inflammatory diseases through T-helper type 17 (TH17) cells.
However, whether or not variants within the IL-23R increase susceptibility to IRIS in western Kenya is unknown. The
objective of the current study was to determine the association between IL-23R gene polymorphisms, CD4+ cell
counts and HIV RNA levels and IRIS in HIV and Schistosoma mansoni co-infected patients undergoing highly active
anti-retroviral therapy (HAART).
Methods: A three-month case–control study was conducted on antiretroviral naïve schistosomiasis/HIV co-infected
fishermen starting HAART in Uyoma Rarieda, Siaya County, Kenya. Seventy one patients were sampled at baseline and
followed up for three months, to establish if they developed Schistosoma-related IRIS. In addition, the CD4+ cell counts
and HIV RNA levels were determined in pre- and post-administration of HAART. Variations at five polymorphic sites of
IL-23R (rs1884444, rs11465754, rs6682925, rs7530511 and rs7539625) based on >10% minor allele frequency in Yoruban
reference population was determined using Allelic Discrimination Assay. The association between the five variants and
susceptibility to IRIS was determined using logistic regression while controlling for potential confounders. In addition,
the functional differences between the baseline CD4 + Cell counts and viral loads were determined using medians
while across IL-23R genotypes were determined using Kruskal-Wallis tests.
Results: Overall, 26 (36.6%) patients developed schistosomiasis-associated IRIS at a median age of 35.5 years. Carriage
of the TT genotype at the non-synonymous rs1884444 T > G relative to GG, was associated with a decreased risk of
schistosomiasis-associated IRIS (OR, 0.25, 95% CI, 0.07-0.96, P = 0.043) while both baseline CD4+ cell counts and viral
loads had no association with IRIS.
Conclusion: These findings indicate that the non-synonymous variant rs1884444 T > G of IL-23R is associated with a
decreased risk to schistosomiasis-associated IRIS. However, additional studies in a larger cohort and with an all inclusive
polymorphic variants in the synonymous and non-synonymous regions need to be evaluated.
Keywords: HAART, IRIS, Non-synonymous, SNP, Schistosomiasis
* Correspondence: collinouma@yahoo.com
2Maseno University, Maseno, Kenya
Full list of author information is available at the end of the article
© 2014 Ogola et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Ogola et al. BMC Infectious Diseases 2014, 14:316
http://www.biomedcentral.com/1471-2334/14/316
Background
Despite the declining incidence of AIDS-related mortality
over past decades, it still remains one of the most com-
mon causes of death, particularly in sub-Saharan Africa,
where resources are limited [1]. A significant number of
AIDS cases develop into severe clinical manifestations
described as Immune Reconstitution Inflammatory Syn-
drome (IRIS) during the first few months of starting highly
active antiretroviral therapy (HAART) [2-6], leading to
additional HIV-related morbidity and mortality. IRIS is
characterized by acute inflammatory responses to chronic
opportunistic infections such as schistosomias, and is
accompanied by a state of immunosuppression, with
the immune system beginning to recover with a response
to a previously acquired opportunistic infection which
results in a heightened inflammatory response that ironic-
ally makes the symptoms of infection worse [2,3,7-12]. The
condition manifest with a wide range of clinical presenta-
tions and is associated with a number of antigenic targets
[13,14], including, for example, antigens from viable repli-
cating infective pathogens during a sub-clinical infection
(unmasking IRIS), or from dead pathogen debris and dying
of non-infective pathogens (paradoxical IRIS), host antigen
(autoimmune disease), tumor antigen and other inflamma-
tory conditions [13-15]. The pathogenesis of IRIS is poorly
understood, however, monocytes and natural killer (NK)
cells involved in innate immunity, inappropriate function
of T-cell, polymorphism in human leukocyte antigen
(HLA) and cytokine-related genes, have been associated
with this clinical condition [16,17].
IL-23R is a type 1 trans-membrane protein found on
dendritic cells, monocytes, activated T-cells and NK cells
[18]. The IL-23R is a heterodimer, comprising the IL-12Rβ1
and a novel sub-unit named IL-23R [18]. The IL-12Rβ1
and the IL-12Rβ2 sub-units also form the IL-12 receptor
(IL-12R). The IL-23R has an extracellular domain made
of a signal sequence, an N-terminal immunoglobulin-like
domain, and two cytokine receptor domains. The intracel-
lular domain of IL-23R has seven tyrosine residues that
can be phosphorylated. Three of the residues are src
homology, two are domain-binding sites while two are
signal transducers and activators of transcription (STAT)
binding sites [19]. Binding of IL-23 to its receptor causes
activation of Janus kinases (Jaks) which phosphorylates
IL-23R at certain locations, thus forming docking sites
for the STATs, and further enabling them to translocate to
the nucleus where transcription of pro-inflammatory genes
such as IL-17 and interferon-γ (IFN-γ) are initiated [19].
IL-23 is responsible for the differentiation and prolifer-
ation of Th17/ThIL-17 cells from naive CD4
+ T cells [20].
Th17 aids in pathogen clearance and tissue inflammation
by expressing elevated levels of the pro-inflammatory
cytokine (IL-17) in response to stimulation, in addition
to IL-1, IL-6, TNF-α, IL-22, and IL-25 (IL-17E) [21].
Other studies have also shown that IL-23-deficient mice
were resistant to central nervous system’s (CNS) auto-
immune inflammation because they were unable to develop
IL-17 producing ThIL-17 cells [22]. Genome-Wide Associ-
ation Studies (GWAS) have also established the IL-23R
gene, as the susceptibility locus associated with some
chronic inflammatory diseases, such as Crohn’s disease,
inflammatory bowel disease and psoriasis [23-27], impli-
cating this receptor in inflammatory diseases. However, to
date, the functional associations between the IL-23 recep-
tor (IL-23R) variants and susceptibility to Schistosoma-
related IRIS in populations resident in Lake Victoria
remains unknown. We hypothesized that the genetic
variants within the synonymous (point mutations) and
non-synonymous (an insertion or deletion of a single
nucleotide in the sequence during transcription leading
to a frameshift mutation) IL-23R gene would be predis-
posing factors for susceptibility to Schistosoma-related
IRIS. Five polymorphisms were selected based on the
frequency of mutant alleles (>10%) in the reference
African Yoruba population following previous studies
that have demonstrated that genes with mutant alleles
having high frequencies are likely to be undergoing
disease selective pressure [28,29]. The hallmark of HIV
infection is characterized by depletion of CD4+ T cells
and concomitant increase in HIV load [30,31]. IL-23
promotes proliferation of memory CD4+ T cells which
are preferentially infected by HIV [19,32]. Despite years
of intensive research, the mechanisms of CD4+ T cells
depletion by the virus has remained widely speculative
and it remain unclear whether or not, variation in the
IL-23 or its receptor genes, could play a role in IRIS
pathogenesis. Our current findings demonstrate that none
of the IL-23R variants were associated with changes in
CD4+ cells or HIV load during HAART. Results further
demonstrated that carriage of the TT genotype at the
rs1884444 T > G relative to GG, was associated with a
decreased risk of schistosomiasis-associated IRIS.
Methods
Study population
The study targeted the fishing community in Uyoma,
Rarieda District, along the shores of Lake Victoria in
Kenya, a group occupationally-exposed to water infested
with the infective stage of Schistosoma mansoni parasite.
The prevalence of schistosomiasis in this population is high
with about a third of them HIV-1 co-infected [33-36].
The following inclusion criteria were employed during
recruitment of the study participants: participants had to
be ≥18 years of age, be permanent resident of the study
area, and willing to sign informed consent form. Other
criteria for inclusion were: having undergone voluntary
HIV counseling and testing in a recognized government
institution, be HAART naïve at the beginning of the
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study, must have been screened for and had a history
of treated schistosomiasis. Exclusion criteria included
presence of other most common co-infections (e.g.
malaria, tuberculosis, hepatitis B) in the populations that
may independently dysregulate immune responses.
HAART naïve individuals were consented, recruited and
underwent parasitological screening for schistosomiasis
and Voluntary Testing and Counseling (VCT) for HIV
prior to enrollment in HAART (this involved prescription
of a combination of three drugs: lamivudine, stavudine
and nevirapine) in a health care provider of their own
choice.
Ethical considerations
Prior to initiation of the study, the scientific and ethical
clearance was obtained from the Scientific Steering Com-
mittee (SSC number 1763) and Ethical Review Committee
(ERC), respectively, based at the Kenya Medical Research
Institute (KEMRI).
Laboratory testing and evaluations
Laboratory testing and evaluations were performed at
baseline, after one month and three months post-
enrollment. Schistosomiasis parasitological screen was
performed by Kato Katz thick stool smear as previously
defined [37]. However, data on HIV load and CD4 cell
counts were both collected at baseline and three
months post-HAART. The CD4 cell counts were per-
formed using BD TruCount (BD Bioscience, San Jose,
California) while HIV loads were determined using
Amplicor HIV-1 Monitor Test (version 1.5) (Roche,
Basel, Switzerland) from plasma stored at −80°C. Mal-
aria parasitemia was determined by microscopy using
Giemsa-stained blood smears while tuberculosis was
determined using the standard tuberculosis skin test
(PPD Skin Test). The Hepatatis B testing was conducted
serologically using the Hepatatis B blood panel tests
(Core Technology, Beijing, China), as per manufacturer’s
instructions.
Schistosomiasis-associated IRIS was defined as either
the re-emergence of symptoms of otherwise successfully
treated schistosomiasis on initiation of HAART or the
production of schistosome eggs by individuals who were
not producing eggs before initiating HAART [38]. The
chronic symptoms of schistosomiasis-associated IRIS
included at least three of the following: hepato-spleno-
megaly; ultra-sound finding or clinical signs of hyperten-
sion; ultra-sound finding or clinical signs of increased
granuloma formation/liver fibrosis; haematuria; and egg
production in stool (whose presence could not be
explained by other possible cause). Laboratory and
clinical data were obtained at each visit and stored in
electronic data base.
Polymorphism genotyping
Genomic DNA was isolated from 2 mL of peripheral
whole blood using Qi-Amp Midi kit (Qiagen, Hilden,
Germany) as per manufactures instructions. A total of 5
polymorphic sites within the IL-23R were selected based
on the mutant’s allele frequencies of over 10% in refer-
ence African Yoruba population (dbSNP: http://www.
ncbi.nlm.nih.gov/SNP/, HAPMAP: http://www.hapmap.
org/index.html.en). The IL-23R polymorphisms identi-
fied were rs7530511, rs1884444, rs11465754, rs6682925
and rs7539625. The polymorphic variants were determined
using TaqMan 5’ Allelic Discrimination–Assay-By-Design
(Applied Biosystems, Foster City, CA). Briefly, the assays
were performed in a total volume of 5 μl (containing
Taqman Universal Master Mix and SNP Genotyping
Assay Mix) with the following amplification protocol:
95°C for 10 min, followed by 40 cycles of 95°C for
15 sec and 60°C for 1 min. Allele-calling was carried out
using allele-specific fluorescence on the ABI StepOnePlus
real-time PCR system (Applied Biosystems, Foster City,
CA, USA). The automated sequence detection software
(SDS) was then used for allelic discrimination (Applied
Biosystems, Foster City, CA).
Statistical analysis
Data was analyzed in SPSS (version 17.0 Chicago, IL).
Proportions and allele frequencies between IRIS patients
and controls were assessed through the use of Pearson
χ2 and Fisher’s exact tests while Kruskal-Wallis test was
used to analyze differences across groups. Medians were
compared using the Mann–Whitney U test. Logistic
regression analyses were used to calculate odds ratios
(OR), 95% confidence interval (CI) and corresponding
P-values for the association of each variant and suscepti-
bility to IRIS, while controlling for the confounding effects
of age and sex. These confounders were controlled for
based on previous studies which have shown that they
independently alter cytokine levels in disease [39]. The
dependent variable in the regression analyses was the
development of IRIS while the independent variables
were the IL-23R genotypes. All P ≤ 0.05 were considered
statistically significant.
Results
Demographic characteristics of the study participants
A total of ninety adults (n = 90) eligible patients were
identified, 19 individuals were excluded from the study
due to incomplete laboratory data. Of the remaining 71
study participants, 35 (49.3%) were males while 36 (50.7%)
were females. A total of 26 (36.6%) of the patients devel-
oped IRIS while forty five (63.4%) did not develop IRIS
and were used as controls. The distribution of the males
vs. females (P = 0.154), median age (P = 0.867), baseline
CD4 cell counts (P = 0.101) and baseline HIV plasma viral
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loads (P = 0.116) were comparable between the IRIS and
non-IRIS patients. These findings demonstrate that demo-
graphic characteristics between the cases and the controls
were fairly comparable in the study population (Table 1).
Prevalence of IL-23R genotypes in S. mansoni-infected
patients undergoing HAART
Samples from the 71 S. mansoni-infected individuals
undergoing HAART were genotyped for the IL-23R
polymorphisms (Table 2). Results revealed a comparable
distribution of variants within the rs7530511 (P = 0.518),
rs1884444 (P = 0.091), rs11465754 (P = 0.426), rs6682925
(P = 0.393), and rs6682925 (P = 0.088) between the IRIS
and non-IRIS patients (Table 2).
Association between IL-23R genotypes and susceptibility
to S. mansoni-related IRIS
In order to determine the association between IL-23R
genotypes and susceptibility to S. mansoni-related IRIS, a
multivariate logistic regression analyses was carried out
while controlling for the confounding effect of age and
sex. Results revealed that relative to the GG genotype,
carriage of the TT genotype at the rs1884444 locus was
associated with a reduced risk to IRIS (OR: 0.25, 95% CI:
0.07-0.96, P = 0.043). However, none of the other variants
were associated with susceptibility to IRIS (Table 3).
The functional role of rs7530511, rs1884444, rs11465754,
rs6682925, rs7539625 and changes in CD4 cell counts
and HIV loads in blood
In order to determine the functional role of IL-23R vari-
ants in conditioning CD4 cell counts and HIV loads, the
medians in cases versus controls were compared using
Mann–Whitney U test, while across genotype compari-
sons was determined using Kruskal-Wallis test. Results in
all the IL-23R variants demonstrated a marked decrease in
HIV load coupled with marked improvement in CD4 cell
counts. Additional across group comparison in genotypes
revealed comparable levels in CD4 cell counts and HIV
viral loads for variants in rs7530511 (P = 0.500, P = 0.405),
rs1884444 (P = 0.414, P = 0.648), rs11465754 (P = 0.782,
P = 0.975), rs6682925 (P = 0.700, P = 0.818), and rs7539625
(P = 0.715, P = 0.863), respectively (data not shown). Taken
together, these results demonstrate that the presence of the
IL-23R genotypes in cases or controls does not alter CD4
cell counts and HIV loads in this population.
Discussion
This study investigated the association between five IL-
23R variants and risk to schistosomiasis-associated IRIS
in a Kenyan population naturally exposed to schisto-
somiasis. We demonstrate that the TT genotype of the
rs1884444 (T > G) SNP in IL-23R gene was associated
with a decreased risk of schistosomiasis-associated IRIS
while the four other variant had no association with
this disease condition in this western Kenyan population.
The rs1884444 is located on exon 2 of IL-23R, and it has
been previously shown to be responsible for the signal
peptide of IL-23R, since variation in this site may interfere
with binding of an exonic splicing enhancer leading to
exon skipping, malformation or alternative splicing
[40]. In addition, this polymorphism results in amino
acid change in codon 3 (His > Gln) and may influence
the ligand-receptor specificity and affinity [40], thereby
modulating the pro-inflammatory effects of Th17 cell, thus
Table 1 Demographic characteristics of the study
participants
IRIS NON-IRIS P-value
Age at enrolment, years 35.5 (28–45) 34 (29–41) 0.867a
Male (n) (%) 14 (53.8) 21 (46.7) 0.154b
Base-line CD4 count 171.5 (112–251) 216 (144–317) 0.101a
Base-line Viral Load 93.2 (9.8-213) 234 (12.0-531) 0.116a
(103xcopies/ml)
Data are median and interquartile range unless stated otherwise. aStatistical
significance determined by Mann–Whitney U test. bStatistical significance
determined by Pearson’s Chi-square tests.
Table 2 The prevalence of IL-23R genotypes in patients
undergoing HAART (IRIS) and non-IRIS
Genotype IRIS Non-IRIS P-value
rs7530511
CC 17 (70.83) 33 (76.74) 0.518a
CT 5 (20.83) 9 (20.93)
TT 2 (8.33) 1 (2.33)
rs1884444
GG 4 (18.18) 16 (39.02) 0.091a
GT 16 (72.73) 18 (43.90)
TT 2 (9.09) 7 (17.07)
rs11465754
AA 7 (26.92) 16 (38.10) 0.426a
AG 16 (61.54) 19 (45.24)
GG 3 (11.54) 7 (16.67)
rs6682925
CC 10 (38.46) 19 (48.72) 0.393a
CG 13 (50.00) 13 (33.33)
GG 3 (11.54) 7 (17.95)
rs7539625
GG 5 (20.83) 16 (36.36) 0.088a
GA 17 (70.83) 19 (43.18)
AA 2 (8.33) 9 (20.45)
aData are proportions (%) as determined by Fishers’ exact test. The targeted
variants were those that had a prevalence of >10% in reference African Yoruba
population (dbSNP and HAP-MAP). There were no significant differences in
proportions of the variants in IRIS versus non-IRIS patients.
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leading to decreased risk to schistosomiasis-associated
IRIS. It would be important to carry out a genome-wide
study in IRIS-diseased versus non-diseased to fully identify
potential genes that may modulate susceptibility to IRIS in
populations naturally exposed to schistosomiasis.
Previous studies [41,42] demonstrated that IL-23/IL-
17 pathway is essential for the development of severe
schistosome egg-induced immunopathology and its ab-
sence cannot be compensated with other mechanisms.
However, the exact molecular mechanism by which
IL-23 regulates Th17 cell and the associated activities
of the IL-23, IL-23R, and their SNPs and susceptibility
to schistosomiasis-associated IRIS are undefined and
require further studies. In the current study, we only
managed to collect data from a total of 26 well-defined
IRIS cases against 45 controls after three months post-
HAART follow-up. This presented us with a challenge
of harnessing enough numbers to effectively carry out
detailed functional associations between the SNPs and
differential changes in CD4+ cell counts and HIV viral
load. Future studies should address the components of
large numbers in a well-designed extensive longitudinal
survey to fully elucidate the sample size effects over
time.
Although previous studies had shown the importance
of IL-23 in mediating the development of pathogenic
CD4+ T-cell population that produces differential IL-17
(a cytokine associated with higher pathology in schisto-
somiasis), we found no association between the risk of
schistosomiasis-associated IRIS and magnitude of change
in CD4+ cell counts or decrease in HIV viral load. Even
though surprising, this may be an indication that the rate
of immune reconstitution is not an important factor in
susceptibility to IRIS [19,43]. These findings contrast
those of earlier studies, which demonstrated that marked
reduction in viral load and magnitude of change in CD4+
cell counts is associated with IRIS risk [44]. The disparity
in the current versus previous findings may be partly due
to the relative frequency of various IRIS events across
the two studies. In the previous studies, IRIS diagnosis
was based on consensus expert opinion, and classified
by mode of presentation (paradoxical worsening of known
opportunistic infection [OI] or unmasking of sub-clinical
disease) while in the current study, IRIS was defined as
either the re-emergence of symptoms of otherwise suc-
cessfully treated chronic schistosomiasis on initiation
of HAART or the production of schistosome eggs by
individuals who were not producing eggs before initiating
them on HAART [38]. The symptoms of schistosomiasis-
associated IRIS included at least three of the following:
hepato-splenomegaly; ultra-sound finding or clinical signs
of hypertension; ultra-sound finding or clinical signs of in-
creased granuloma formation/liver fibrosis; haematuria;
and egg production in stool (whose presence could not be
explained by other possible cause). Such variations in re-
gional definition of disease may lead to differences in both
gene and functional associations. It may be plausible to
develop regional definition to ascertain whether or not
differences exist in disease manifestations.
Conclusion
In conclusion, we demonstrate for the first time, in this
case–control study from a high-risk Kenyan population
that the non-synonymous SNP rs1884444 (His3Gln) of
IL-23R gene was associated with a decreased risk of
schistosomiasis-associated IRIS. However, none of the
SNPs were functionally associated with CD4+ cells and
HIV viral loads. Further studies incorporating functional
evaluations of the IL-23/IL-23R on IL-23R carrier cells
in larger cohorts are warranted to validate our findings.
Ethical approval
The study was approved by the Ethics Review Committee
of the Kenya Medical Research Institute. Informed written
consent was obtained from all the participants in the
study.
Table 3 The association between IL-23R variants and
susceptibility to IRIS
IRIS
Genotypes OR 95% CI P-value
rs7530511
CC 1.00
CT 1.05 0.30–3.68 0.308
TT 3.64 0.30–43.62 0.386
rs1884444
GG 1.00
GT 0.24 0.04–1.51 0.129
TT 0.25 0.07–0.96 0.043
rs11465754
AA 1.00
AG 0.40 0.12–1.33 0.136
GG 0.37 0.07–1.84 0.222
rs6682925
CC 1.00
GG 1.95 0.64–5.94 0.240
GG 0.77 0.16–3.81 0.748
rs7539625
GG 1.00
GA 0.34 0.10–1.14 0.080
AA 0.25 0.05–1.40 0.116
Data are presented as Odds Ratio (OR) and 95% Confidence Interval (95% CI).
Data analyzed by multivariate logistic regression analyses controlling for the
confounding effects of age and sex.
P-values in bold are significant at P ≤ 0.05. The reference group in each of the
analysis was the most prevalent genotype.
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